Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Chubb
Daiichi Sankyo
Express Scripts
Harvard Business School
Moodys
Teva
Dow
UBS

Generated: May 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,101,574

« Back to Dashboard

Summary for Patent: 7,101,574
Title:Pharmaceutical composition containing fenofibrate and the preparation method
Abstract:The invention concerns a pharmaceutical composition containing micronized fenofibrate, a surfactant and a binding cellulose derivative, as solubilizing adjuvant, preferably hydroxypropylmethylcellulose. The cellulose derivative represents less than 20 wt. % of the composition. The association of micronized fenofibrate with a binding cellulose derivative, as solubilizing adjuvant and a surfactant enables enhanced bioavailability of the active principle. The invention also concerns a method for preparing said composition without using any organic solvent.
Inventor(s): Criere; Bruno (Gravigny, FR), Suplie; Pascal (Montaure, FR), Chenevier; Philippe (Montreal, CA)
Assignee: Laboratoires des Produits Ethiques Ethypharm (Houdan, FR)
Application Number:10/030,262
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,101,574
Patent Claim Types:
see list of patent claims
Composition; Formulation; Dosage form; Process;

Drugs Protected by US Patent 7,101,574

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Lupin Atlantis ANTARA (MICRONIZED) fenofibrate CAPSULE;ORAL 021695-001 Nov 30, 2004 AB RX Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Lupin Atlantis ANTARA (MICRONIZED) fenofibrate CAPSULE;ORAL 021695-003 Nov 30, 2004 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,101,574

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France99 08923Jul 09, 1999
PCT Information
PCT FiledJuly 07, 2000PCT Application Number:PCT/FR00/01971
PCT Publication Date:January 18, 2001PCT Publication Number: WO01/03693

Non-Orange Book US Patents Family Members for Patent 7,101,574

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,563,042 Pharmaceutical composition containing fenofibrate and method for the preparation thereof ➤ Sign Up
7,863,331 Pharmaceutical composition containing fenofibrate and method for the preparation thereof ➤ Sign Up
8,658,212 Pharmaceutical composition containing fenofibrate and method for the preparation thereof ➤ Sign Up
8,529,952 Pharmaceutical composition containing fenofibrate and method for the preparation thereof ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Teva
Covington
Dow
QuintilesIMS
Healthtrust
Cipla
Harvard Business School
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.